Nephrotoxicity of targeted therapy used to treat lung cancer

被引:4
作者
Li, Qiuling [1 ]
Lin, Jieshan [1 ,2 ]
Hao, Guojun [1 ]
Xie, Aihua [1 ]
Liu, Shuangxin [2 ]
Tang, Bin [1 ]
机构
[1] Zhongshan Peoples Hosp, Blood Purificat Ctr, Dept Nephrol, Zhongshan, Peoples R China
[2] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Nephrol, Guangzhou, Peoples R China
关键词
lung cancer; targeted therapy; EGFR TKIs; ALK TKIs; nephrotoxicity; RENAL CYST FORMATION; OPEN-LABEL; EGFR-TKI; ACQUIRED-RESISTANCE; ALK INHIBITORS; ADVERSE EVENTS; SINGLE-ARM; PHASE-I; CRIZOTINIB; GEFITINIB;
D O I
10.3389/fimmu.2024.1369118
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lung cancer is the leading cause of cancer-related death worldwide, especially non-small cell lung cancer. Early diagnosis and better treatment choices have already provided a more promising prognosis for cancer patients. In targeted therapy, antagonists target specific genes supporting cancer growth, proliferation and metastasis. With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents must be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. Drug-related nephrotoxicity has attracted attention when initiating cancer therapy. Our review aims to summarize the adverse renal effects caused by targeted therapy during lung cancer treatment, mainly focusing on EGFR and ALK tyrosine kinase inhibitors. Also, we discuss the possible mechanism of the side effect and provide managements to help improve the renal function in clinical practice.
引用
收藏
页数:13
相关论文
共 114 条
[1]   Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism [J].
Abourehab, Mohammed A. S. ;
Alqahtani, Alaa M. ;
Youssif, Bahaa G. M. ;
Gouda, Ahmed M. .
MOLECULES, 2021, 26 (21)
[2]   Hypophosphatemia in cancer patients [J].
Adhikari, Shreedhar ;
Mamlouk, Omar ;
Rondon-Berrios, Helbert ;
Workeneh, Biruh T. .
CLINICAL KIDNEY JOURNAL, 2021, 14 (11) :2304-2315
[3]   Computational Analysis of Epidermal Growth Factor Receptor Mutations Predicts Differential Drug Sensitivity Profiles toward Kinase Inhibitors [J].
Akula, Sravani ;
Kamasani, Swapna ;
Sivan, Sree Kanth ;
Manga, Vijjulatha ;
Vudem, Dashavantha Reddy ;
Kancha, Rama Krishna .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (05) :721-726
[4]   Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) [J].
Barlesi, Fabrice ;
Mazieres, Julien ;
Merlio, Jean-Philippe ;
Debieuvre, Didier ;
Mosser, Jean ;
Lena, Herve ;
Ouafik, L'Houcine ;
Besse, Benjamin ;
Rouquette, Isabelle ;
Westeel, Virginie ;
Escande, Fabienne ;
Monnet, Isabelle ;
Lemoine, Antoinette ;
Veillon, Remi ;
Blons, Helene ;
Audigier-Valette, Clarisse ;
Bringuier, Pierre-Paul ;
Lamy, Regine ;
Beau-Faller, Michele ;
Pujol, Jean-Louis ;
Sabourin, Jean-Christophe ;
Penault-Llorca, Frederique ;
Denis, Marc G. ;
Lantuejoul, Sylvie ;
Morin, Franck ;
Quan Tran ;
Missy, Pascale ;
Langlais, Alexandra ;
Milleron, Bernard ;
Cadranel, Jacques ;
Soria, Jean-Charles ;
Zalcman, Gerard .
LANCET, 2016, 387 (10026) :1415-1426
[5]   Minimal Change Disease Induced by Lorlatinib [J].
Betton, Maureen ;
Gounant, Valerie ;
Sannier, Aurelie ;
Hanouna, Guillaume ;
Goujon, Jean-Michel ;
Brosseau, Solenn ;
Zalcman, Gerard ;
Chemouny, Jonathan M. .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :E154-E156
[6]   Anaplastic lymphoma kinase inhibitors and their effect on the kidney [J].
Bonilla, Marco ;
Jhaveri, Kenar D. ;
Izzedine, Hassan .
CLINICAL KIDNEY JOURNAL, 2022, 15 (08) :1475-1482
[7]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21609, 10.3322/caac.21492]
[8]   VEGF in biological control [J].
Breen, Ellen C. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2007, 102 (06) :1358-1367
[9]   Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma [J].
Broniscer, Alberto ;
Baker, Suzanne J. ;
Stewart, Clinton F. ;
Merchant, Thomas E. ;
Laningham, Fred H. ;
Schaiquevich, Paula ;
Kocak, Mehmet ;
Morris, E. Brannon ;
Endersby, Raelene ;
Ellison, David W. ;
Gajjar, Amar .
CLINICAL CANCER RESEARCH, 2009, 15 (02) :701-707
[10]   Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer [J].
Califano, Raffaele ;
Greystoke, Alastair ;
Lal, Rohit ;
Thompson, Joyce ;
Popat, Sanjay .
LUNG CANCER, 2017, 111 :51-58